Title:
VARIABLE NEW ANTIGEN RECEPTORS (VNARS) DIRECTED AGAINST TRANSFERRIN RECEPTOR (TFR) AND THEIR USE
Document Type and Number:
WIPO Patent Application WO/2016/077840
Kind Code:
A3
Abstract:
This invention relates TfR-specific binding moieties with high specificity for and functional interaction with the transferrin receptor ("TfR"). These moieties may be used to carry biomolecules across membranes, including the blood brain barrier and the gastrointestinal tract. The invention relates more specifically to nurse shark VNAR single chain antibodies that bind to TfR, conjugates and compositions comprising a TfR specific VNAR binding moiety, methods for preparing them, diagnostic and therapeutic methods of use in vitro or in vivo, Other uses for TfR specific VNAR binding moieties of the invention include, e.g., regulating the interaction of iron-charged transferrin with TfR (receptor cycling or cell surface presentation), such as may be therapeutic in treatment of certain cancer cells and tumors of various tissue types.
More Like This:
Inventors:
HÄSLER JULIEN (GB)
RUTKOWSKI JULIA LYNN (US)
WICHER KRZYSZTOF BARTLOMIEJ (GB)
RUTKOWSKI JULIA LYNN (US)
WICHER KRZYSZTOF BARTLOMIEJ (GB)
Application Number:
PCT/US2015/060948
Publication Date:
July 28, 2016
Filing Date:
November 16, 2015
Export Citation:
Assignee:
OSSIANIX INC (US)
International Classes:
C07K16/28; A61K39/395; A61P1/00; A61P25/00; C07K16/40; C07K16/46; C12N15/13
Domestic Patent References:
| WO2010033913A1 | 2010-03-25 | |||
| WO2013177062A2 | 2013-11-28 | |||
| WO2015200883A2 | 2015-12-30 |
Other References:
YU Y JOY ET AL: "Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target", SCIENCE TRANSLATIONAL MEDICINE, AAAS - AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 3, no. 84 84ra44, 25 May 2011 (2011-05-25), pages 1 - 8, XP008148394, ISSN: 1946-6242, DOI: 10.1126/SCITRANSLMED.3002230
KOVALEVA MARINA ET AL: "Shark variable new antigen receptor biologics - a novel technology platform for therapeutic drug development", EXPERT OPINION ON BIOLOGICAL THERAPY, INFORMA HEALTHCARE, UK, vol. 14, no. 10, 1 October 2014 (2014-10-01), pages 1527 - 1539, XP009187644, ISSN: 1744-7682
SHAO ET AL: "Rapid isolation of IgNAR variable single-domain antibody fragments from a shark synthetic library", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 44, no. 4, 1 January 2007 (2007-01-01), pages 656 - 665, XP005622948, ISSN: 0161-5890, DOI: 10.1016/J.MOLIMM.2006.01.010
JULIEN HÄSLER ET AL: "Species cross-reactive single domain antibodies (VNARs) to the transferrin receptor 1 (TfR-1) that cross the BBB Selection of hu/mo cross-reactive anti- TfR-1 VNARs", 13 December 2014 (2014-12-13), XP055251302, Retrieved from the Internet [retrieved on 20160218]
KOVALEVA MARINA ET AL: "Shark variable new antigen receptor biologics - a novel technology platform for therapeutic drug development", EXPERT OPINION ON BIOLOGICAL THERAPY, INFORMA HEALTHCARE, UK, vol. 14, no. 10, 1 October 2014 (2014-10-01), pages 1527 - 1539, XP009187644, ISSN: 1744-7682
SHAO ET AL: "Rapid isolation of IgNAR variable single-domain antibody fragments from a shark synthetic library", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 44, no. 4, 1 January 2007 (2007-01-01), pages 656 - 665, XP005622948, ISSN: 0161-5890, DOI: 10.1016/J.MOLIMM.2006.01.010
JULIEN HÄSLER ET AL: "Species cross-reactive single domain antibodies (VNARs) to the transferrin receptor 1 (TfR-1) that cross the BBB Selection of hu/mo cross-reactive anti- TfR-1 VNARs", 13 December 2014 (2014-12-13), XP055251302, Retrieved from the Internet
Attorney, Agent or Firm:
WILSON, M. Lisa et al. (5204 Delafield AveBronx, New York, US)
Download PDF: